Clinical Trial Update: Efficacy and Safety of RTH258 Versus Aflibercept - Study 1 [Phase 3]

View source ↗

Summary

Completed Phase 3 trial (Study 1) comparing RTH258 (brolucizumab) with aflibercept in neovascular age-related macular degeneration, with efficacy and safety res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Neovascular Age-related Macular Degeneration

Drugs mentioned

• BEOVU (BROLUCIZUMAB)
• EYLEA (Aflibercept)

Snippet

Sponsor: Alcon Research | Conditions: Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization | Phase 3 | Status: COMPLETED | Results posted: 2019-10-31